About: Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
Creator	Angeletti, Silvia Ciccozzi, Massimo Storici, Paola Benedetti, Francesca Gallo, Robert Ippodrino, Rudy Marini, Bruna Pachetti, Maria Zella, Davide Giudici, Fabiola Masciovecchio, Claudio Mauro, Elisabetta
Source	Medline; PMC
abstract	BACKGROUND: SARS-CoV-2 is a RNA coronavirus responsible for the pandemic of the Severe Acute Respiratory Syndrome (COVID-19). RNA viruses are characterized by a high mutation rate, up to a million times higher than that of their hosts. Virus mutagenic capability depends upon several factors, including the fidelity of viral enzymes that replicate nucleic acids, as SARS-CoV-2 RNA dependent RNA polymerase (RdRp). Mutation rate drives viral evolution and genome variability, thereby enabling viruses to escape host immunity and to develop drug resistance. METHODS: We analyzed 220 genomic sequences from the GISAID database derived from patients infected by SARS-CoV-2 worldwide from December 2019 to mid-March 2020. SARS-CoV-2 reference genome was obtained from the GenBank database. Genomes alignment was performed using Clustal Omega. Mann–Whitney and Fisher-Exact tests were used to assess statistical significance. RESULTS: We characterized 8 novel recurrent mutations of SARS-CoV-2, located at positions 1397, 2891, 14408, 17746, 17857, 18060, 23403 and 28881. Mutations in 2891, 3036, 14408, 23403 and 28881 positions are predominantly observed in Europe, whereas those located at positions 17746, 17857 and 18060 are exclusively present in North America. We noticed for the first time a silent mutation in RdRp gene in England (UK) on February 9th, 2020 while a different mutation in RdRp changing its amino acid composition emerged on February 20th, 2020 in Italy (Lombardy). Viruses with RdRp mutation have a median of 3 point mutations [range: 2–5], otherwise they have a median of 1 mutation [range: 0–3] (p value < 0.001). CONCLUSIONS: These findings suggest that the virus is evolving and European, North American and Asian strains might coexist, each of them characterized by a different mutation pattern. The contribution of the mutated RdRp to this phenomenon needs to be investigated. To date, several drugs targeting RdRp enzymes are being employed for SARS-CoV-2 infection treatment. Some of them have a predicted binding moiety in a SARS-CoV-2 RdRp hydrophobic cleft, which is adjacent to the 14408 mutation we identified. Consequently, it is important to study and characterize SARS-CoV-2 RdRp mutation in order to assess possible drug-resistance viral phenotypes. It is also important to recognize whether the presence of some mutations might correlate with different SARS-CoV-2 mortality rates.
has issue date	2020-04-22(xsd:dateTime)
bibo:doi	10.1186/s12967-020-02344-6
bibo:pmid	32321524
has license	cc-by
sha1sum (hex)	b43559b44f0423915513c0eb2d49b9d10e76aba6
schema:url	https://doi.org/10.1186/s12967-020-02344-6
resource representing a document's title	Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
has PubMed Central identifier	PMC7174922
has PubMed identifier	32321524
schema:publication	J Transl Med
resource representing a document's body	covid:b43559b44f0423915513c0eb2d49b9d10e76aba6#body_text
is schema:about of	named entity 'mutation rate' named entity 'immunity' named entity 'SARS-CoV-2' named entity 'replicate' named entity 'host' named entity 'viruses' named entity 'SARS-CoV-2' named entity 'RNA dependent RNA polymerase' named entity 'viruses' named entity 'SARS-CoV-2' named entity 'RdRp' named entity 'Mutation rate' named entity 'viral evolution' named entity 'mutation rate' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'amino acid' named entity 'mutation' named entity 'antiviral drugs' named entity 'Nidovirales' named entity 'RdRp' named entity 'GISAID' named entity 'RNA polymerase' named entity 'mutation' named entity 'mutation' named entity 'RdRp' named entity 'France' named entity 'p-value' named entity 'coronavirus' named entity 'SARS-CoV-2' named entity 'RdRp' named entity 'SARS-CoV' named entity 'Cambodia' named entity 'epidemics' named entity 'hydrophobic' named entity 'HCV protease inhibitor' named entity 'Betacoronavirus' named entity 'Middle East Respiratory Syndrome' named entity 'protein' named entity 'RdRp' named entity 'polymerase' named entity 'nucleotide' named entity 'United Kingdom' named entity 'genetic information' named entity 'drug-resistance' named entity 'viral genomes' named entity 'antiviral drugs' named entity 'ExoN' named entity 'Ribavirin' named entity 'SARS-CoV-2' named entity 'Europe' named entity 'catalytic domain' named entity 'mutation' named entity 'virulence' named entity 'RdRp' named entity 'mutation' named entity 'phenotypes' named entity 'RdRp' named entity 'SARS-CoV' named entity 'mutation rate' named entity 'ExoN' named entity 'amino acid' named entity 'RdRp' named entity 'viral mutations' named entity 'mutation' named entity 'China' named entity 'Italy' named entity 'Exact test' named entity '95% CI' named entity 'Spain'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software